Literature DB >> 9558162

Early radiographic joint space narrowing and erosion and later malalignment in rheumatoid arthritis: a longitudinal analysis.

T Pincus1, H A Fuchs, L F Callahan, E P Nance, J J Kaye.   

Abstract

OBJECTIVE: To analyze the time course of development of radiographic erosion, joint space narrowing, and malalignment in a longitudinal study of radiographs of the hands and wrists of 58 patients with rheumatoid arthritis (RA) taken over 18 years.
METHODS: Among 210 consecutive patients in a reported cohort, 58 had at least one prior available radiograph 2-18 years earlier. A total of 141 hand and wrist radiographs in the 58 patients were scored for joint space narrowing, erosion, and malalignment in individual joints.
RESULTS: Of the 58 patients studied, all developed joint space narrowing, 56 (96.5%) developed erosions, while only 24 (41.4%) developed malalignment. In radiographs of 22 patient studied within the first 5 years of disease, joint space narrowing was seen in 17 (77.3%), erosion in 16 (72.7%), and malalignment in only 3 (13.6%). Radiographic progression was seen in all 36 patients in whom the interval between radiographs was longer than 2 years.
CONCLUSION: Joint space narrowing and erosion are seen in hand radiographs of most patients with RA seen in treatment centers within the first 5 years of disease. By contrast, malalignment develops in fewer patients, and generally only after 5 years of disease.

Entities:  

Mesh:

Year:  1998        PMID: 9558162

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

1.  Patients with rheumatoid arthritis in clinical care.

Authors:  J S Smolen; D Aletaha
Journal:  Ann Rheum Dis       Date:  2004-03       Impact factor: 19.103

Review 2.  Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Iñigo Bermejo; Shijie Ren; Emma Simpson; Mark Clowes; David L Scott; Adam Young; Matt Stevenson
Journal:  Pharmacoeconomics       Date:  2018-12       Impact factor: 4.981

Review 3.  Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Iñigo Bermejo; Matt Stevenson; Rachel Archer; John W Stevens; Edward Goka; Mark Clowes; David L Scott; Adam Young
Journal:  Pharmacoeconomics       Date:  2017-11       Impact factor: 4.981

Review 4.  Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Lesley Uttley; Iñigo Bermejo; Shijie Ren; Marrissa Martyn-St James; Ruth Wong; David L Scott; Adam Young; Matt Stevenson
Journal:  Pharmacoeconomics       Date:  2018-09       Impact factor: 4.981

Review 5.  Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Shijie Ren; Iñigo Bermejo; Emma Simpson; Ruth Wong; David L Scott; Adam Young; Matt Stevenson
Journal:  Pharmacoeconomics       Date:  2018-07       Impact factor: 4.981

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.